ORPHA:716
Phenylketonuria
Also known as: PKU
Publications
18,012
Trials
93
Interventional, condition-specific
Researchers
1,309
Distinct authors in sample
Gene link
PAH
Definitive
Readiness
6/6
Stages with a signal
Clinical definition (Orphanet)
A rare inborn error of amino acid metabolism characterized by elevated blood phenylalanine and low levels or absence of phenylalanine hydroxylase . If not detected early or left untreated, the disorder manifests with mild to severe mental disability.
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0009861
- MeSH:D010661
- OMIM:261600
- UMLS:C0031485
- NCIT:C81315
Additional Mondo synonyms (4)
PAH deficiency · hyperphenylalaninemia, non-PKU mild · phenylalanine hydroxylase deficiency · phenylketonuria
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
6/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Definitive — PAH
- LiteraturePresent
18,012 matched papers (7,658 in last 10 years) Source
- Phenotype characterisedPresent
84 HPO annotations (e.g. Eczematoid dermatitis; Hypopigmentation of the skin; Seizure) Source
- Animal modelPresent
7 genotype models (Mus musculus) Source
- Orphan designationPartial
3 EMA designations (none yet with FDA orphan-indication approval) — e.g. adeno-associated virus vector encoding human phenylalanine hydroxylase Source
- Interventional trialPresent
93 matched on ClinicalTrials.gov (19 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (PAH).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
84
Associated phenotypes · MONDO:0009861
- Eczematoid dermatitis
- Hypopigmentation of the skin
- Seizure
- Abnormal cerebral white matter morphology
- Musty odor
Showing 5 of 84 — open Monarch for the full list.
Animal models (Monarch / Alliance)
7
Model associations linked to this Mondo ID
- hph1/hph1 [background:] involves: C57BL/6 * CBA/Ca·MGI:3639091·Mus musculus
- Hnf1atm1Mya/Hnf1atm1Mya [background:] involves: 129S2/SvPas·MGI:3610388·Mus musculus
- Pahem1Skym/Pahem1Skym [background:] C57BL/6J-Pahem1Skym·MGI:6715269·Mus musculus
- Pahenu3/Pahenu3 [background:] involves: BTBR·MGI:3587816·Mus musculus
- Pahenu2/Pahenu2 [background:] involves: BTBR·MGI:3587815·Mus musculus
- Pahenu2/Pahenu2 [background:] BTBR-Pahenu2/J·MGI:5300789·Mus musculus
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
3
Designations · no FDA orphan-indication approval yet
- EMA adeno-associated virus vector encoding human phenylalanine hydroxylaseTreatment of phenylalanine hydroxylase deficiency · 16/12/2019 · WithdrawnEMA designation
- EMA adeno-associated virus serotype HSC15, containing human homology arms, expressing human phenylalanine hydroxylaseTreatment of phenylalanine hydroxylase deficiency · 16/03/2022 · WithdrawnEMA designation
- EMA adeno-associated virus serotype HSC15 expressing human phenylalanine hydroxylaseTreatment of phenylalanine hydroxylase deficiency · 14/12/2018 · WithdrawnEMA designation
Sources: FDA OOPD · EMA orphan designations
Open Targets candidates
8
Drugs / clinical candidates · MONDO_0009861
- LABAFENOGENE MARSELECOBAC·phase 3
- AMMONIA SOLUTION, STRONG·phase 2
- PHENYLALANINE·phase 2
- BEVUFENOGENE NOFEPARVOVEC·phase 1 2
- PEGVALIASE·approval
- SAPROPTERIN·approval
- SAPROPTERIN DIHYDROCHLORIDE·approval
- SEPIAPTERIN·approval
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
18,012
18,012 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
18,012 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
7,658 in the last 10 years · low confidence
Phrase hits: 16,470 · MeSH hits: 0
Who's working on it?
1,309
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01MacDonald A8 papers · 2026
Dietetic Department, Birmingham Children's Hospital, Birmingham B4 6NH, UK. Electronic address: Anita.Macdonald@nhs.net.
Papers in Europe PMC - 02Harding CO7 papers · 2026
Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, USA.
Papers in Europe PMC - 03Longo N6 papers · 2026
Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA.
Papers in Europe PMC - 04Maillot F6 papers · 2026
Department of Internal Medicine, INSERM 1253 "iBraiN", University of Tours, Tours, France.
Papers in Europe PMC - 05Muntau AC6 papers · 2026
University Children's Hospital, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Papers in Europe PMC - 06Pinto A6 papers · 2026
Dietetic Department, Birmingham Children's Hospital, Birmingham B4 6NH, UK. Electronic address: Alex.Pinto@nhs.net.
Papers in Europe PMC - 07van Spronsen FJ6 papers · 2026
Division of Metabolic Diseases, Beatrix Children's Hospital, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands.
Papers in Europe PMC - 08Walkowiak D6 papers · 2026
Poznan University of Medical Sciences, Department of Organization and Management in Health Care, Marii Magdaleny Str. 14, 61-861 Poznań, Poland.
Papers in Europe PMC - 09Ashmore C5 papers · 2026
Birmingham Children's Hospital, Steelhouse Lane, Birmingham B4 6NH, UK.
Papers in Europe PMC - 10Daly A5 papers · 2026
Birmingham Children's Hospital, Steelhouse Lane, Birmingham B4 6NH, UK.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
93
interventional trials for this specific condition
93 interventional trials matched this specific condition name; 19 currently recruiting in our sample.
Data as of 11 September 2026 · last trial check 28 July 2026
93 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 98.4th percentile).
low confidence · 98.4th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
93 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06971731·RECRUITING·A Study of JNT-517 in Participants With Phenylketonuria (PKU)
Not reviewed·Conditions: Phenylketonuria·Matched via name phrase
- NCT07713758·NOT YET RECRUITING·A Trial to Examine if Repinatrabit is Processed Differently in Adults With Reduced Liver or Kidney Function Compared to Adults With Normal Liver and Kidney Function
Not reviewed·Conditions: Phenylketonuria·Matched via name phrase
- NCT06718842·RECRUITING·Walking Program in Fatty Liver Children With Phenylketonuria
Not reviewed·Conditions: Phenylketonurias · Non Alcoholic Fatty Liver·Matched via name phrase
- NCT06628128·RECRUITING·A Long-Term Study of JNT-517 in Participants With Phenylketonuria
Not reviewed·Conditions: Phenylketonuria (PKU)·Matched via name phrase
- NCT06941532·RECRUITING·GMP Powdered Substitutes in PKU and TYR
Not reviewed·Conditions: Phenylketonuria · Tyrosinemia·Matched via name phrase
- NCT07241234·RECRUITING·A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria
Not reviewed·Conditions: Phenylketonuria·Matched via name phrase
- NCT07694440·RECRUITING·A Study of MZE782 in Adults With PKU
Not reviewed·Conditions: Phenylketonuria (PKU)·Matched via name phrase
- NCT07318909·NOT YET RECRUITING·To Evaluate the Safety and Efficacy of GS1168 Injection in Adult Phenylketonuria
Not reviewed·Conditions: Phenylketonuria (PKU)·Matched via name phrase
- NCT07220265·RECRUITING·Impact of Phenylalanine Elevations on Brain and Cognition in Adult PKU Carriers
Not reviewed·Conditions: Carrier of Phenylketonuria · Healthy·Matched via name phrase
- NCT07526909·RECRUITING·Effect of Different Meal Types Given Before Exercise on Plasma Amino Acid Levels and Metabolic Control Parameters in Classical Phenylketonuria Patients Undergoing Aerobic and Resistance Exercises
Not reviewed·Conditions: Phenylketonuria·Matched via name phrase
- NCT07477691·RECRUITING·Immune Modulation During Palynziq® Treatment in Adults (IMPALA)
Not reviewed·Conditions: Phenylketonuria·Matched via name phrase
- NCT06337864·RECRUITING·Effect of Large Neutral Amino Acids in Adults With Classical Phenylketonuria
Not reviewed·Conditions: Brain Diseases · Brain Diseases, Metabolic · Brain Diseases, Metabolic, Inborn · Genetic Diseases, Inborn·Matched via name phrase
- NCT04969809·NOT YET RECRUITING·Comparison of Atherogenic Risk Factors and Efficacy of Nutritional Treatment Among Adult Phenylketonuria Patients
Not reviewed·Conditions: Phenylketonurias · Nutritional and Metabolic Diseases·Matched via name phrase
- NCT07685210·RECRUITING·GenSci144 Tablets Phase I Clinical Trial
Not reviewed·Conditions: Phenylketonuria·Matched via name phrase
- NCT06302348·RECRUITING·A Study of Sepiapterin in Participants With Phenylketonuria (PKU)
Not reviewed·Conditions: Phenylketonuria·Matched via name phrase
Observational and natural-history studies
51 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT06305234·RECRUITING·A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)
Not reviewed·Conditions: Phenylketonuria (PKU)·Matched via name phrase
- NCT07551921·NOT YET RECRUITING·PheCheck™ Validation Study
Not reviewed·Conditions: Phenylketonuria (PKU) and Hyperphenylalaninemia·Matched via name phrase
- NCT07406009·NOT YET RECRUITING·The Psychosocial Functioning of Adults With Phenylketonuria.
Not reviewed·Conditions: Phenylketonuria (PKU)·Matched via name phrase
- NCT07728032·RECRUITING·Impact Of A Phe-Restricted Diet On Gut Health In Children With PKU
Not reviewed·Conditions: Phenylketonuria·Matched via name phrase
- NCT05579548·RECRUITING·A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and Breastfeeding
Not reviewed·Conditions: Phenylketonuria, Maternal·Matched via name phrase
- NCT05813678·RECRUITING·A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)
Not reviewed·Conditions: Phenylketonuria (PKU)·Matched via name phrase
- NCT06969209·RECRUITING·Brain Aging in Phenylketonuria
Not reviewed·Conditions: Phenylketonuria (PKU)·Matched via name phrase
- NCT04404530·RECRUITING·Nutritional Impacts of Palynziq on Patients With Phenylketonuria (PKU)
Not reviewed·Conditions: Phenylketonurias·Matched via name phrase
- NCT07484945·RECRUITING·Multiomics Approach in Adult Patients With Phenylketonuria
Not reviewed·Conditions: Phenylketonuria (PKU)·Matched via name phrase
- NCT06940193·ENROLLING BY INVITATION·A Self-test Home-use Blood Phenylalanine Monitoring System Under the Brand Name Egoo Phe System Has Been Developed for Measurement of Phenylalanine (Phe) in Individuals Diagnosed With Phenylketonuria (PKU): The Study Purpose is to Evaluate Accuracy and Usability
Not reviewed·Conditions: Phenylketonuria (PKU)·Matched via name phrase
- NCT06289348·RECRUITING·Announcement of Rare Metabolic Diseases in Systematic Newborn Screening: the Phenylketonuria Experience.
Not reviewed·Conditions: Phenylketonuria·Matched via name phrase
- NCT07698743·RECRUITING·Eating Disorders in Patients With Phenylketonuria
Not reviewed·Conditions: Phenylketonuria·Matched via name phrase
- NCT05128149·RECRUITING·Metabolic Control and Patient Well-being in Phenylketonuria: do Guidelines Make a Difference?
Not reviewed·Conditions: Phenylketonurias·Matched via name phrase
- NCT04348708·ENROLLING BY INVITATION·Long-Term Follow Up Study of Subjects Previously Administered HMI 102
Not reviewed·Conditions: Phenylketonuria · PAH Deficiency·Matched via name phrase
- NCT07703020·ENROLLING BY INVITATION·Prevalence and Determinants of Obesity in PKU Patients
Not reviewed·Conditions: Phenylketonuria (PKU)·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 31 · after dedupe 29 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 29 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (29)
- ctis·2024-519121-38-01·Authorised·A phase 1 first-in-human study of a phenylalanine-binding polymer (phelimin) in healthy volunteers and adult, classical PKU patients
skipped — LLM skipped (--skip-llm)
- ctis·2025-522630-31-00·Authorised, ongoing·Evaluation of AG-181 in Subjects 18 to 69 Years of Age With Phenylketonuria
skipped — LLM skipped (--skip-llm)
- ctis·2024-519554-37-00·Authorised, ongoing·A Phase 3, Double-Blind, Randomized, Two-Period, Multicenter, Placebo-Controlled, Efficacy and Safety Study of JNT-517 for the Treatment of Participants with Phenylketonuria
skipped — LLM skipped (--skip-llm)
- ctis·2024-514435-20-00·Authorised, ongoing·A Phase 3b Open-Label Study of Long-Term Neurocognitive Outcomes in Children With Phenylketonuria Treated With Sepiapterin (EPIPHENY)
skipped — LLM skipped (--skip-llm)
- ctis·2023-506963-32-00·Cancelled·A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of mRNA 3210 in Participants with Phenylketonuria
skipped — LLM skipped (--skip-llm)
- ctis·2024-510875-39-00·Expired·A Phase 3 Multi-Center Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase in Adolescent Subjects (Ages 12-17) with Phenylketonuria Featuring an Open-Label Randomized Two-Arm (Active vs Diet-Only Control) Design
skipped — LLM skipped (--skip-llm)
- ctis·2023-506238-61-00·Cancelled·A Phase 3, Randomized, Crossover, Open-Label, Active-Controlled Study of Sepiapterin versus Sapropterin in Participants With Phenylketonuria ≥2 years of Age
skipped — LLM skipped (--skip-llm)
- ctis·2023-509229-31-00·Cancelled·A Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria
skipped — LLM skipped (--skip-llm)
- ctis·2022-502932-37-00·Cancelled·A Phase 3, Double-blind, Placebo-controlled, Randomized Withdrawal Study to Evaluate the Efficacy and Safety of SYNB1934 in Patients with PKU (SYNPHENY-3)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN62698625·Recruiting·FAD - Food for ADHD and Depression
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12620764·No longer recruiting·Understanding how phenylketonuria affects the brain, heart, metabolism, and gut from childhood to adulthood
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13949559·No longer recruiting·Trial of alginates in throat symptoms
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12192375·Recruiting·Longitudinal physiological changes in inherited metabolic disorders
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN71987471·No longer recruiting·Corticosteroids plus standard of care treatment versus standard of care treatment alone to prevent heart complications in Kawasaki disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN38904316·Stopped·Acceptability and tolerability of a new phe-free protein substitute for the dietary management of patients with phenylketonuria, aged ≥16 years
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11016729·No longer recruiting·Examining the absorption of three phenylalanine-free amino acid mixtures, one of which was formulated with the Physiomimic modified-release technology, in healthy volunteers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16431108·No longer recruiting·Family History Lifestyle Study
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12514406·No longer recruiting·The effect of auditory integration therapy on brain cognitive function in autism
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN52903778·No longer recruiting·WEight Loss in Learning Disabilities and Obesity (WELLDO): A weight loss intervention for adults with learning disabilities and obesity
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17091496·No longer recruiting·Casein+ study: Dietary strategies to augment post-prandial muscle protein accretion
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN52169198·No longer recruiting·Gaviscon double action versus placebo study using the BRAVO System
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN26166772·No longer recruiting·Blackcurrant juice study: a study to investigate the biokinetics and effects of a blackcurrant juice on endothelial function
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN51472596·No longer recruiting·Treatment Alternatives for acute Sore Throat in Everyday practice
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN51638237·No longer recruiting·A phase 1, single-center, double-blind study of AM103 in healthy volunteers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN95777824·No longer recruiting·Regenerative effects of erythropoietin in burn and scald injuries
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Phenylketonuria — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26Directly listed under NPRD Group 2.
Group 2 — long-term / lifelong lower-cost interventions
NPRD envisages State Government support for dietary formulae, hormones, and other lower-cost interventions. This is a different route from the central CoE ₹50 lakh pathway; ask your state health department and a CoE which channel applies.
Central CoE funding may also apply depending on current rules — confirm with a notified Centre of Excellence. Do not assume the ₹50 lakh ceiling covers Group 2 by default. Verify
Centres of Excellence (15)
- All India Institute of Medical Sciences (AIIMS) — New Delhi, Delhi
- Maulana Azad Medical College — New Delhi, Delhi
- Sanjay Gandhi Post Graduate Institute of Medical Sciences — Lucknow, Uttar Pradesh
- Post Graduate Institute of Medical Education and Research (PGIMER) — Chandigarh, Chandigarh
- Centre for DNA Fingerprinting & Diagnostics with Nizam’s Institute of Medical Sciences — Hyderabad, Telangana
- King Edward Memorial Hospital — Mumbai, Maharashtra
- Institute of Post-Graduate Medical Education and Research (IPGMER) — Kolkata, West Bengal
- Centre for Human Genetics with Indira Gandhi Hospital — Bengaluru, Karnataka
- Institute of Child Health and Hospital for Children (ICH & HC) — Chennai, Tamil Nadu
- All India Institute of Medical Sciences (AIIMS) — Jodhpur, Rajasthan
- Sree Avittam Thirunal Hospital (SAT), Government Medical College — Thiruvananthapuram, Kerala
- All India Institute of Medical Sciences (AIIMS) — Bhopal, Madhya Pradesh
- Regional Institute of Medical Sciences (RIMS) — Imphal, Manipur
- All India Institute of Medical Sciences (AIIMS) — Patna, Bihar
- Assam Medical College & Hospital — Dibrugarh, Assam
Voluntary contributions / crowdfunding (separate from CoE funding): https://rarediseases.mohfw.gov.in/
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Phenylketonuria" OR "PAH deficiency" OR "hyperphenylalaninemia, non-PKU mild" OR "phenylalanine hydroxylase deficiency") OR ("PAH syndrome" OR "PAH-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Phenylketonuria" OR "PAH deficiency" OR "hyperphenylalaninemia, non-PKU mild" OR "phenylalanine hydroxylase deficiency"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 93 interventional · 51 observational · 1 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: PKU
Confidence reasoning
- Preferred label is short or not clearly distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T15:01:19.825Z
